Latest News

ASH Action Alert: Contact Congress Today in Support of Federal Research Funding

Deadline March 14

Details >

Shape the Future of Hematology by Joining ASH Trainee Council

Deadline to apply is March 30

Details >

MSHO Position Statement Regarding Proposed NCI and NIH Funding Cuts

Details >

ACT Now! Tell Congress to Extend Telehealth Flexibilities

Without congressional action, current Medicare telehealth flexibilities will expire on March 31

Details >

FDA Approves BeiGene's TEVIMBRA® (tislelizumab-jsgr), in Combination With Platinum-Containing Chemotherapy, for Treatment of Adults With Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Details >

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers, and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education

It is important that our members are aware of meetings, webinars, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation

The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board

MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
Report Broken Link

Welcome

Latest News

ASH Action Alert: Contact Congress Today in Support of Federal Research Funding

Deadline March 14

Shape the Future of Hematology by Joining ASH Trainee Council

Deadline to apply is March 30

MSHO Position Statement Regarding Proposed NCI and NIH Funding Cuts

ACT Now! Tell Congress to Extend Telehealth Flexibilities

Without congressional action, current Medicare telehealth flexibilities will expire on March 31

FDA Approves BeiGene's TEVIMBRA® (tislelizumab-jsgr), in Combination With Platinum-Containing Chemotherapy, for Treatment of Adults With Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Advocacy

Education

Research

MSHO Foundation

Job Board

Report Broken Links